EMA to consider if risks of these medicines require further restrictions of use
The European Medicines Agency (EMA) has started a review looking at the use of valproate-containing medicines in the treatment of women and girls who are pregnant or of childbearing age. These medicines are approved nationally in the EU to treat epilepsy, bipolar disorder and in some countries, migraine, and have been previously reviewed by the Agency.
More information on the following link:
New review of valproate use in pregnancy and women of childbearing age
